Geron makes a drug that stops cancer cells from multiplying by blocking their telomerase, like cutting the fuel line on a runaway engine. It targets rare blood cancers called myelodysplastic syndromes and myelofibrosis.
Revenue comes from selling imetelstat, which brought in USD 0.18B in 2025, but the company still loses money—net loss of USD 0.09B that year. Gross margins are high (97%), yet operating costs eat everything, so no profit yet.
Imetelstat is the only telomerase inhibitor approved for these blood cancers, giving it a unique niche that Bristol Myers Squibb's Reblozyl and Incyte's Jakafi don't cover directly. But the moat is eroding as Celgene and others test similar mechanisms, and the
None yet
None yet
Geron Corporation (GERN) shows strong seasonal trends with a high win rate and average positive move, suggesting a potential short-term bullish outlook based on historical data.
Main discussion
Increasing unusual call option volume: $REAL $PR $SAN $AS $ALHC $EVTL $CYPH $BNTX $OPRA $NXPI $GERN $AMPL
$GERN is your highest seasonality setup into next week with a 90% win rate and +5.2%avrg move over the last 20 years. https://t.co/34itHACaL1
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
